- Advertisement -spot_img
28.2 C
Lagos
HomeMetro NewsNigeria becomes 2nd nation after Ghana to approve Oxford malaria vaccine

Nigeria becomes 2nd nation after Ghana to approve Oxford malaria vaccine

- Advertisement -spot_img

Nigeria has granted provisional approval to Oxford University’s R21 malaria vaccine, according to the National Agency for Food and Drug Administration and Control (NAFDAC), making it the second country to do so after Ghana last week.

The approvals are unusual as they have come before the publication of final-stage trial data for the vaccine.

“A provisional approval of the R21 malaria vaccine was recommended, and this shall be done in line with the WHO’s malaria vaccine implementation guideline,” NAFDAC said in a statement.

Malaria, a mosquito-borne disease, kills more than 600,000 people each year, most of them African babies and children.

Nigeria, the continent’s most populous nation, is the world’s worst-affected country, with 27 percent of global cases and 32 percent of global deaths, according to a 2021 World Health Organization (WHO) report.

It was unclear when the R21 vaccine may be rolled out in Nigeria or Ghana, as other regulatory bodies, including the WHO, are still assessing its safety and effectiveness.

Childhood vaccines in the poorest parts of Africa are typically co-funded by international organizations such as Gavi, the vaccine alliance, only after getting WHO approval.

READ ALSO: Aviation workers disrupt domestic flights over pay, conditions

“While granting the approval, the Agency has also communicated the need for expansion of the clinical trial conducted to include a phase 4 clinical trial and pharmacovigilance study to be carried out in Nigeria,” NAFDAC’s director-general, Mojisola Christianah Adeyeye said in the statement.

“Overall, the R21 malaria vaccine dossier complied substantially with best international standards with which the dossier was benched-marked as mentioned above. The joint review committee concluded that the data on the R21 malaria vaccine were robust and met criteria for efficacy, safety, and quality,” she said.

“It was also adjudged that the vaccine’s known and potential benefits outweigh its known and potential risks, thereby supporting the manufacturer’s recommended use.

“The brief on the approval of the R21 Malaria vaccine has been communicated to the minister of health and national primary health care development agency for appropriate actions toward immunisation in the respective population.”

Mid-stage data from the R21 trial involving more than 400 young children were published in September, showing vaccine efficacy of between 70 and 80% at 12 months following the fourth dose.

Data from an ongoing phase 3 clinical trial involving 4,800 children in Burkina Faso, Kenya, Mali, and Tanzania are due to be published in the coming months.

Oxford has a deal with the Serum Institute of India to produce up to 200 million doses of R21 annually.

The first malaria vaccine, Mosquirix from British drugmaker GSK, was endorsed by the WHO last year, but a lack of funding is thwarting GSK’s capacity to produce enough doses.

Join Our Mailing List!

* indicates required
- Advertisement -spot_img
- Advertisement -spot_img
Must Read
Related News
- Advertisement -spot_img